natgillin/translations-raw huggingface dataset:
Når voriconazol initieres hos patienter, der allerede får omeprazol, anbefales det at halvere omeprazoldosis.
When initiating voriconazole in patients already receiving omeprazole, it is recommended that the omeprazole dose be halved.
Metabolismen af andre protonpumpehæmmere, som er CYP2C19 substrater, kan også hæmmes af voriconazol.
The metabolism of other proton pump inhibitors which are CYP2C19 substrates may also be inhibited by voriconazole.
Orale antikonceptiva:
Oral Contraceptives:
Samtidig administration af voriconazol og et oralt kontraceptivt præparat (1 mg norethisteron og 0, 035 mg ethinylestradiol; 1 gang dagligt) hos raske kvindelige forsøgspersoner fører til en stigning i Cmax og AUCτ af ethinylestradiol (henholdsvis 36% og 61%), og norethisteron (henholdsvis 15% og 53%).
Coadministration of voriconazole and an oral contraceptive (1 mg norethisterone and 0.035 mg ethinylestradiol; once daily) in healthy female subjects resulted in increases in the Cmax and AUCτ of ethinylestradiol (36% and 61% respectively) and norethisterone (15% and 53% respectively).
Voriconazols Cmax og AUCτ stiger med henholdsvis 14% og 46%.
Voriconazole Cmax and AUCτ increased by 14% and 46% respectively.
Det forventes, at voriconazol - niveauerne vender tilbage til normalværdien under en pillefri uge.
It is expected that the voriconazole levels will return to standard levels during the pill-free week.
Da ratioen mellem norethisteron og ethinylestradiol forbliver den samme under interaktion med voriconazol, vil den kontraceptive aktivitet sandsynligvis ikke blive påvirket.
As the ratio between norethisterone and ethinylestradiol remained similar during interaction with voriconazole, their contraceptive activity would probably not be affected.
Skønt der ikke ses en stigning i incidensen af hormon - relaterede bivirkninger i den kliniske interaktionsundersøgelse, kan højere østrogen - og progestagenniveau måske forårsage især kvalme og menstruelle forstyrrelser.
Although no increase in the incidence of hormonal related adverse events was observed in the clinical interaction study, higher estrogen and progestagen levels may cause notably nausea and menstrual disorders.
Orale kontraceptiva, som indeholder doser større end 1 mg northisteron og 0, 035 mg ethinylestradiol, er ikke undersøgte.
Oral contraceptives containing doses other than 1 mg norethisterone and 0.035 mg ethinylestradiol have not been studied.
Antiretrovirale midler:
Antiretroviral Agents:
Indinavir (CYP3A4- hæmmer og - substrat):
Indinavir (CYP3A4 inhibitor and substrate):
Indinavir (800 mg 3 gange dagligt) har ingen signifikant effekt på voriconazols Cmax og AUCτ.
Indinavir (800 mg three times daily) had no significant effect on voriconazole Cmax, Cmin and AUCτ.
Voriconazol har ingen signifikant effekt på Cmax, Cmin og AUCτ af indinavir (800 mg 3 gange dagligt).
Voriconazole did not have a significant effect on Cmax and AUCτ of indinavir (800 mg three times daily).
Andre HIV- proteasehæmmere (CYP3A4- hæmmere):
Other HIV protease inhibitors (CYP3A4 inhibitors):
In vitro forsøg tyder på, at voriconazol måske kan hæmme metabolismen af HIV- proteasehæmmere (f. eks. saquinavir, amprenavir og nelfinavir).
In vitro studies suggest that voriconazole may inhibit the metabolism of HIV protease inhibitors (e. g. saquinavir, amprenavir and nelfinavir).
In vitro forsøg viser også, at voriconazols metabolisme måske hæmmes af HIV- proteasehæmmere.
In vitro studies also show that the metabolism of voriconazole may be inhibited by HIV protease inhibitors.
Dog kan resultater af kombinationsbehandling med voriconazol og andre HIV- proteasehæmmere ikke forudsiges hos mennesker alene på baggrund af in vitro forsøg.
However results of the combination of voriconazole with other HIV protease inhibitors cannot be predicted in humans only from in vitro studies.
Patienter bør monitoreres omhyggeligt for mulig lægemiddeltoksicitet og/ eller behandlingssvigt ved samtidig administration af voriconazol og HIV- proteasehæmmere.
Patients should be carefully monitored for any occurrence of drug toxicity and/ or loss of efficacy during the co-administration of voriconazole and HIV protease inhibitors.
Efavirenz (en non- nucleosid reverse transcriptase- hæmmer) (CYP450- induktor; CYP3A4- hæmmer og - substrat):
Efavirenz (a non-nucleoside reverse transcriptase inhibitor) (CYP450 inducer; CYP3A4 inhibitor and substrate):
Steady state efavirenz (400 mg oralt 1 gang dagligt) nedsatte steady state Cmax og AUCτ af voriconazol med et gennemsnit på henholdsvis 61% og 77% hos raske forsøgspersoner.
Standard doses of voriconazole and standard doses of efavirenz must not be coadministered Steady-state efavirenz (400 mg orally once daily) decreased the steady state Cmax and AUCτ of voriconazole by an average of 61% and 77%, respectively, in healthy subjects.
Voriconazol øgede ved steady state i det samme studie steady state efavirenz Cmax og AUCτ med et gennemsnit på henholdsvis 38% og 44% hos raske forsøgspersoner.
In the same study voriconazole at steady state increased the steady state Cmax and AUCτ of efavirenz by an average of 38% and 44% respectively, in healthy subjects.
10 I et separat forsøg med raske forsøgspersoner gav samtidig administration af 300 mg voriconazol 2 gange dagligt og lavdosis efavirenz (300 mg 1 gang dagligt) ikke tilstrækkelig eksponering af voriconazol.
In a separate study in healthy subjects, voriconazole dose of 300mg BID in combination with low dose efavirenz (300 mg once daily) did not lead to sufficient voriconazole exposure.
Hos raske forsøgspersoner ses et fald i AUCτ på 7% og en stigning i Cmax på 23% efter samtidig administration af voriconazol 400 mg 2 gange dagligt og efavirenz 300 mg oralt 1 gang dagligt sammenlignet med voriconazol 200 mg 2 gange dagligt anvendt alene.
Following coadministration of voriconazole 400 mg twice daily with efavirenz 300 mg orally once daily, in healthy subjects, the AUCτ of voriconazole was decreased by 7% and Cmax was increased
AUCτ af efavirenz stiger med 17%, og Cmax er ækvivalent sammenlignet med efavirenz 600 mg 1 gang dagligt anvendt alene.
(The AUCτ of efavirenz was increased by 17% and Cmax was equivalent compared to efavirenz 600 mg once daily alone).
Disse forskelle er ikke klinisk signifikante.
These differences were not considered to be clinically significant.
Når voriconazol anvendes samtidigt med efavirenz, bør voriconazols vedligeholdelsesdosis øges til 400 mg 2 gange dagligt, og efavirenz- dosis bør nedsættes med 50%, dvs. til 300 mg 1 gang dagligt (se pkt.
When voriconazole is coadministered with efavirenz, voriconazole maintenance dose should be increased to 400 mg twice daily and the efavirenz dose should be reduced by 50%, i. e. to 300 mg once daily (see section 4.2).
Når behandlingen med voriconazol stoppes, bør initialdosis af efavirenz genoptages.
When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored.
Non- nucleosid reverse transcriptase- hæmmere (NNRTI) (CYP3A4- substrater, hæmmere eller CYP450- induktorer):
Non-nucleoside reverse transcriptase inhibitors (NNRTI) (CYP3A4 substrates, inhibitors or CYP450 inducers):
In vitro forsøg viser, at metabolismen af voriconazol kan hæmmes af delavirdin.
In vitro studies show that the metabolism of voriconazole may be inhibited by delavirdine.
Skønt det ikke er undersøgt, kan metabolismen af voriconazol induceres af nevirapin.
Although not studied, the metabolism of voriconazole may be induced by nevirapine.
Et in vivo forsøg viste, at voriconazol hæmmes af metabolismen af efavirenz.
An in-vivo study showed that voriconazole inhibited the metabolism of efavirenz.
Voriconazol kan også hæmme NNRTIs metabolisme foruden efavirenz.
Voriconazole may also inhibit the metabolism of NNRTIs besides efavirenz.
Patienter bør omhyggeligt monitoreres for mulig lægemiddeltoksicitet og/ eller behandlingssvigt ved samtidig administration af voriconazol og NNRTIer.
Patients should be carefully monitored for any occurrence of drug toxicity and/ or lack of efficacy during the coadministration of voriconazole and NNRTIs.
4. 2 og 4. 4).
Dose adjustments are required when voriconazole is co-administered with efavirenz (see sections 4.2 and 4.4).
Graviditet Der foreligger ikke tilstrækkelig data om brugen af VFEND hos gravide kvinder.
Pregnancy There are no adequate data from the use of VFEND in pregnant women.
Kvinder i den fertile alder Kvinder i den fertile alder bør altid anvende effektiv antikonceptionsmetode under behandlingen.
Women of child-bearing potential Women of child-bearing potential must always use effective contraception during treatment.
Amning Udskillelsen af voriconazol i modermælk er ikke undersøgt.
Lactation The excretion of voriconazole into breast milk has not been investigated.
VFEND kan påvirke evnen til at føre motorkøretøj eller betjene maskiner i moderat grad.
VFEND may have a moderate influence on the ability to drive and use machines.
Det kan forårsage forbigående og reversible ændringer af synet, herunder sløret, ændret/ forøget visuel perception og/ eller fotofobi.
It may cause transient and reversible changes to vision, including blurring, altered/ enhanced visual perception and/ or photophobia.
Sikkerhedsprofilen af voriconazol er baseret på en integreret sikkerhedsdatabase med data fra mere end 2000 personer (1655 patienter i kliniske studier).
The safety profile of voriconazole is based on an integrated safety database of more than 2000 subjects (1655 patients in therapeutic trials).
Databasen repræsenterer en heterogen population indeholdende patienter med maligne hæmatologiske sygdomme, HIV- inficerede patienter med øsofageal candidiasis og refraktære svampeinfektioner, non- neutropene patienter med candidæmi eller aspergillosis og raske forsøgspersoner.
This represents a heterogeneous population, containing patients with haematological malignancy, HIV infected patients with oesophageal candidiasis and refractory fungal infections, non-neutropenic patients with candidaemia or aspergillosis and healthy volunteers.
561 patienter er blevet behandlet med voriconazol i mere end 12 uger, heraf fik 136 personer voriconazol i mere end 6 måneder.
Five hundred and sixty one patients had a duration of voriconazole therapy of greater than 12 weeks, with 136 patients receiving voriconazole for over 6 months.
11 Da størstedelen af studierne var åbne, er alle kausale bivirkninger, hvor der er en mulig årsagssammenhæng, anført efter systemorganklasse og frekvens (meget almindelig > 1/ 10, almindelig > 1/ 100 og < 1/ 10, ikke almindelig > 1/ 1000 og < 1/ 100, sjælden < 1/ 1000 og meget sjælden < 1/ 10. 000) i tabellen nedenfor.
In the table below, since the majority of the studies were of an open nature all causality adverse events, by system organ class and frequency (very common ≥ 1/ 10, common ≥ 1/ 100 and < 1/ 10,
Inden for hver enkelt frekvensgruppe er bivirkningerne opstillet efter, hvor alvorlige de er.
11 uncommon ≥ 1/ 1000 and < 1/ 100, rare, ≥ 1/ 10 000 and < 1/ 1000 and very rare, < 1/ 10 000) if possibly causally related are listed.
De hyppigst rapporterede bivirkninger var synsforstyrrelse, pyreksi, udslæt, opkastning, kvalme, diarré, hovedpine, perifere ødemer og abdominalsmerter.
The most commonly reported adverse events were visual disturbances, pyrexia, rash, vomiting, nausea, diarrhoea, headache, peripheral oedema and abdominal pain.
Bivirkningernes sværhedsgrad var generelt mild til moderat.
The severity of the adverse events was generally mild to moderate.
Systemorganklasser Undersøgelser
System Organ Class Investigations
Forhøjede leverfunktionsværdier (herunder ASAT, ALAT, alkalisk fosfatase, GGT, LDH, bilirubin), forhøjet serum- kreatinin
Elevated liver function tests (including ASAT, ALAT, alkaline phosphatase, GGT, LDH, bilirubin), blood creatinine increased
EKG- korrigeret forlængelse af QT- interval, serum- carbamid, forhøjet kolesteroltal
Electrocardiogram QT corrected interval prolonged, blood urea increased, blood cholesterol increased
Meget almindelig Ikke almindelig
Very common Uncommon
Perifere ødemer Ventrikulær flimren, ventrikulær arytmi, synkope, supraventrikulær arytmi, supraventrikulær takykardi, takykardi, bradykardi
Oedema peripheral Ventricular fibrillation, ventricular arrhythmia, syncope, supraventricular arrhythmia, supraventricular tachycardia, tachycardia, bradycardia
Torsades de pointes, ventrikulær takykardi, komplet AV- blok, grenblok, nodal arytmi
Torsades de pointes, ventricular tachycardia, atrioventricular complete block, bundle branch block, nodal rhythm
Blod - og lymfesystem Almindelig
Blood and Lymphatic system disorders Common
Pancytopeni, knoglemarvsdepression, leukopeni, trombocytopeni, purpura, anæmi
Pancytopenia, bone marrow depression, leukopenia, thrombocytopenia, purpura, anaemia
Dissemineret intravaskulær koagulation, agranulocytose, lymfadenopati, eosinofili
Disseminated intravascular coagulation, agranulocytosis, lymphadenopathy, eosinophilia
Meget almindelig Almindelig Ikke almindelig Sjælden
Nervous system disorders Very common Common Uncommon Rare
Hovedpine Svimmelhed, konfusion, tremor, agitation, paræstesi Hjerneødem, ataksi, diplopi, vertigo, hypæstesi Kramper, encephalopati, Guillain- Barre syndrom, ekstrapyramidale symptomer
Headache Dizziness, confusional state, tremor, agitation, paraesthesia Brain oedema, ataxia, diplopia, vertigo, hypoaesthesia Convulsion, encephalopathy, Guillain-Barre syndrome, extrapyramidal symptoms
4. 4), kromatopsi og fotofobi)
Visual disturbances (including blurred vision (see Section 4.4), chromatopsia and photophobia)
4. 4), nystagmus, scleritis, blepharitis
Papilloedema (see Section 4.4), optic nerve disorder (including optic neuritis, see Section 4.4), nystagmus, scleritis, blepharitis
Retinablødning, optisk atrofi, okulogyr, mælket kornea
Retinal haemorrhage, optic atrophy, oculogyration, corneal opacity
Hypoacusis, tinnitus
Ear and labyrinth disorders Rare Hypoacusis, tinnitus
Akut respiratory distress syndrome, lungeødem, åndedrætsbesvær, brystsmerter
Acute respiratory distress syndrome, pulmonary oedema, respiratory distress, chest pain
12 Mave- tarmkanalen Meget almindelig Almindelig
12 Gastrointestinal disorders Very common Uncommon
Abdominalsmerter, kvalme, opkastning, diarré Pancreatitis, peritonitis, duodenitis, gingivitis, glossitis, tungeødem, dyspepsi, obstipation
Abdominal pain, nausea, vomiting, diarrhoea Pancreatitis, peritonitis, duodenitis, gingivitis, glossitis, swollen tongue, dyspepsia, constipation
Nyrer og urinveje
Dysgeusia
Meget almindelig Almindelig Sjælden
Renal and urinary disorders Common Uncommon Rare
Akut nyresvigt, hæmaturi Nefritis, proteinuri Nekrose i nyretubuli
Renal failure acute, haematuria Nephritis, proteinuria Renal tubular necrosis
Hud og subkutane væv Meget almindelig Almindelig
Skin and subcutaneous tissue disorders Very common Common
Udslæt Eksfoliativ dermatitis, ansigtsødem, lysfølsomme hudreaktioner, makulopapuløst hududslæt, makuløst hududslæt, papuløst hududslæt, læbebetændelse, pruritus, alopeci, erythem
Rash Exfoliative dermatitis, face oedema, photosensitivity reaction, maculo-papular rash, macular rash, papular rash, cheilitis, pruritus, alopecia, erythema
Stevens- Johnsons syndrom, angioneurotisk ødem, allergisk dermatitis, urticaria, lægemiddeloverfølsomhedsreaktioner, psoriasis
Stevens-Johnson syndrome, angioneurotic oedema, allergic dermatitis, urticaria, drug hypersensitivity, psoriasis
Toksisk epidermal nekrolyse, erythema multiforme, lupus erythematosus discoides
Toxic epidermal necrolysis, erythema multiforme, discoid lupus erythematosis
Knogler, led, muskler og bindevæv Meget almindelig Almindelig Sjælden
Musculoskeletal and connective tissue disorders Common Uncommon Rare
Rygsmerter Arthritis Hypertoni
Back pain Arthritis Hypertonia
Binyrebarkinsufficiens Hypertyreose, hypotyreose
Adrenal insufficiency Hyperthyroidism, hypothyroidism
Metabolisme og ernæring Almindelig
Metabolism and nutrition system disorders Common
Hypoglykæmi, hypokaliæmi
Hypoglycaemia, hypokalaemia
Infektioner og parasitære sygdomme Almindelig Sjælden
Infections and infestation Common Rare
Gastroenteritis, influenza- lignende sygdom Pseudomembranøs colitis
Gastroenteritis, influenza-like illness Pseudomembranous colitis
Hypotension, tromboflebitis, flebitis Lymphangitis
Hypotension, thrombophlebitis, phlebitis Lymphangitis
Almene symptomer og reaktioner på administrationsstedet Meget almindelig Almindelig
General disorders and administrative site conditions Very common Common
Pyreksi Reaktioner på injektionsstedet/ inflammation, kuldegysning, asteni
Pyrexia Injection site reaction / inflammation, chills, asthenia,
Almindelig Ikke almindelig
Immune system disorders Common Uncommon
Sinuitis Anafylaktoid reaktion, overfølsomhedsreaktioner
Sinusitis Anaphylactoid reaction, hypersensitivity
Lever og galdeveje Meget almindelig Almindelig Sjælden
13 Hepato-biliary disorders Common Uncommon
Icterus, kolestatisk icterus Leversvigt, hepatitis, hepatomegali, cholecystitis, cholelithiasis Leverkoma
Jaundice, cholestatic jaundice Hepatic failure, hepatitis, hepatomegaly, cholecystitis, cholelithiasis
Psykiske forstyrrelser
Rare
13
Hepatic coma
Almindelig Sjælden
Psychiatric disorders
Depression, angst, hallucinationer Søvnløshed
Depression, anxiety, hallucination Insomnia
Synsforstyrrelser I kliniske forsøg er voriconazol- behandlingsrelaterede synsforstyrelser meget almindelige.
Visual disturbances In clinical trials, voriconazole treatment-related visual disturbances were very common.
30% af personerne ændret/ forøget visuel perception, sløret syn, ændret farvesyn eller fotofobi.
In these studies, short-term as well as long-term treatment, approximately 30% of subjects experienced altered/ enhanced visual perception, blurred vision, colour vision change or photophobia.
Disse synsforstyrrelser er forbigående og fuldt reversible og er for størstedelen spontant gået over inden for 60 minutter, og der ses ingen klinisk betydende visuelle langtidsvirkninger.
These visual disturbances were transient and fully reversible, with the majority spontaneously resolving within 60 minutes and no clinically significant long-term visual effects were observed.
Synsforstyrrelsen er generelt mild, og resulterer sjældent i afbrydelse af behandling og har ikke været forbundet med langtidsvirkninger.
The visual disturbances were generally mild, rarely resulted in discontinuation and were not associated with long-term sequelae.
Synsforstyrrelser kan være forbundet med højere plasmakoncentrationer og/ eller doser.
Visual disturbances may be associated with higher plasma concentrations and/ or doses.
ERG- ændringerne progredierede ikke over 29 dages behandling og var fuldt reversible ved seponering af voriconazol.
The ERG changes did not progress over 29 days of treatment and were fully reversible on withdrawal of voriconazole.
Dermatologiske reaktioner Dermatologiske reaktioner var almindelige hos patienter behandlet med voriconazol i kliniske studier, men disse patienter havde alvorlige tilgrundliggende sygdomme, og fik samtidig behandling med anden medicin.
Dermatological reactions Dermatological reactions were common in patients treated with voriconazole in clinical trials, but these patients had serious underlying diseases and were receiving multiple concomitant medications.
Patienterne har i sjældne tilfælde udviklet alvorlige kutanreaktioner, herunder Stevens- Johnsons syndrom, toksisk epidermal nekrolyse og erythema multiforme under behandling med VFEND.
Patients have rarely developed serious cutaneous reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme during treatment with VFEND.
4. 4).
Photosensitivity reactions have been reported, especially during long-term therapy (see also section 4.4).
Leverfunktionsprøver I voriconazols kliniske program var den samlede incidens af klinisk signifikante transaminaseafvigelser 13, 4% (200/ 1493) hos personer behandlet med voriconazol.
Liver Function Tests The overall incidence of clinically significant transaminase abnormalities in the voriconazole clinical programme was 13.4% (200/ 1493) of subjects treated with voriconazole.
Leverfunktionsafvigelserne kan associeres med højere plasmakoncentrationer og/ eller doser.
Liver function test abnormalities may be associated with higher plasma concentrations and/ or doses.
Hos patienter med andre alvorlige tilgrundliggende sygdomme er voriconazol i sjældne tilfælde blevet forbundet med alvorlig levertoksicitet.
Voriconazole has been infrequently associated with cases of serious hepatic toxicity in patients with other serious underlying conditions.
4. 4).
This includes cases of jaundice, and rare cases of hepatitis and hepatic failure leading to death (see section 4.4).
Sikkerheden af voriconazol er undersøgt hos 245 pædiatriske patienter i alderen 2 til < 12 år, som blev behandlet med voriconazol i farmakokinetiske studier (87 pædiatriske patienter) og i ” compassionate use ” programmer (158 pædiatriske patienter).
Paediatric Use The safety of voriconazole was investigated in 245 paediatric patients aged 2 to < 12 years who were treated with voriconazole in pharmacokinetic studies (87 paediatric patients) and in compassionate use programs (158 paediatric patients).
Bivirkningsprofilen er ens for de 245 pædiatriske patienter og for voksne.
The adverse event profile of these 245 paediatric patients was similar to that in adults.
Hos de 22 patienter under 2 år, som blev behandlet med voriconazol i et ” compassionate use ” program, er følgende bivirkninger (for hvilke en sammenhæng med voriconazol ikke kan udelukkes) rapporteret:
In the 22 patients less than 2 years old who received voriconazole in a compassionate use programme, the following adverse events (for which a relationship to voriconazole could not be excluded) were reported: photosensitivity reaction (1), arrhythmia (1), pancreatitis (1),
Lysfølsomme reaktioner (1), arytmi (1), pancreatitis (1), forhøjet serum- bilirubin (1), forhøjet antal leverenzymer (1), udslæt (1) og papilødem (1).
14 blood bilirubin increased (1), hepatic enzymes increased (1), rash (1) and papilloedema (1).
En enkelt bivirkning af fotofobi, der varede 10 minutter, blev rapporteret.
A single adverse event of photophobia of 10 minutes duration was reported.
J02A C03 Antimykotika til systemisk anvendelse – triazolderivater
J02A C03 Antimycotics for Systemic Use – Triazole derivatives
Voriconazol udviser bredspektret antimykotisk aktivitet in vitro med antimykotisk styrke over for Candida arter (herunder fluconazol resistente C. krusei og resistente stammer af C. glabrata og C. albicans) og fungicid aktivitet over for alle undersøgte Aspergillus arter.
Mechanism of action In vitro, voriconazole displays broad-spectrum antifungal activity with antifungal potency against Candida species (including fluconazole resistant C. krusei and resistant strains of C. glabrata and C. albicans) and fungicidal activity against all Aspergillus species tested.
Virkemåden er en hæmning af svampe cytochrom P450- medieret 14α- sterol demethylering, som er et essentielt trin i ergosterol biosyntesen.
Its mode of action is inhibition of fungal cytochrome P450-mediated 14α -sterol demethylation, an essential step in ergosterol biosynthesis.
Der er i dyreforsøg set korrelation mellem mindste hæmmende koncentrationsværdier og effekt over for eksperimentelle mycoser.
In animal studies there is a correlation between minimum inhibitory concentration values and efficacy against experimental mycoses.
I modsætning hertil, synes der i kliniske studier ikke at være korrelation mellem mindste hæmmende koncentrationsværdier og det kliniske resultat.
By contrast, in clinical studies, there appears to be no correlation between minimum inhibitory concentration values and clinical outcome.
Der synes derudover ikke at være korrelation mellem plasmaniveauer og klinisk resultat.
Furthermore, there does not appear to be a correlation between plasma levels and clinical outcome.
Dette er typisk for azol- antimykotika.
This is typical of azole antimycotics.